CLEVELAND, Aug. 6 /PRNewswire/ -- ChanTest, a leading provider of specialized laboratory testing services for drug discovery and development, announced that it recently completed a private equity financing with Ampersand Ventures. ChanTest has experienced strong and profitable growth since its inception in 1998 and currently employs 60 people in its Cleveland, Ohio, laboratories. This financing will enable ChanTest to pursue strategic investments that expand the company’s offering through its continued development of the world’s most comprehensive library of ion channel-expressing cell lines. Terms of the transaction were not disclosed.
